Figure 4.
Figure 4. Long-term therapeutic efficacy of AAV-cFVIII in hemophilia A dogs. Elisa, Vector, and Junior received 6 × 1012, 1.5 × 1013, and 2.7 × 1013vg/kg AAV2 vector, respectively; Alexis and Maurizio, 1.0 × 1013vg/kg AAV6 vector; and Floopers, 1.0 × 1013vg/kg AAV8 vector. (A) Plasma FVIII activities as measured by Coatest and converted to percentage of normal canine FVIII activity of 7000 mU/mL. (B) Whole-blood clotting time (WBCT) measured before and after vector infusion. The normal range of canine WBCT is 2 to 6 minutes.

Long-term therapeutic efficacy of AAV-cFVIII in hemophilia A dogs. Elisa, Vector, and Junior received 6 × 1012 , 1.5 × 1013 , and 2.7 × 1013 vg/kg AAV2 vector, respectively; Alexis and Maurizio, 1.0 × 1013 vg/kg AAV6 vector; and Floopers, 1.0 × 1013 vg/kg AAV8 vector. (A) Plasma FVIII activities as measured by Coatest and converted to percentage of normal canine FVIII activity of 7000 mU/mL. (B) Whole-blood clotting time (WBCT) measured before and after vector infusion. The normal range of canine WBCT is 2 to 6 minutes.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal